IFNγ synergizes with IL-1β to up-regulate MMP-9 secretion in a cellular model of central nervous system tuberculosis

FASEB Journal

Volumn 21, Issue 2, 2007, Pages 356-365

  Harris, James E ^a   Fernandez Vilaseca, Marc ^a   Elkington, Paul T G ^a   Horncastle, Donna E ^a   Graeber, Manuel B ^a   Friedland, Jon S ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Astrocyte; Gelatinase B; JAK STAT; MAP kinase; Monocyte; Mycobacterium tuberculosis

Indexed keywords

DEXAMETHASONE; GAMMA INTERFERON; GELATINASE B; INTERLEUKIN 1BETA; JANUS KINASE 2; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; STAT1 PROTEIN; STAT3 PROTEIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; JANUS KINASE;

ARTICLE; BACTERIUM CULTURE; BRAIN DEGENERATION; BRAIN TISSUE; CENTRAL NERVOUS SYSTEM INFECTION; CENTRAL NERVOUS SYSTEM TUBERCULOSIS; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; MONOCYTE; MYCOBACTERIUM TUBERCULOSIS; NEUROPATHOLOGY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS INHIBITION; SIGNAL TRANSDUCTION; TRANSACTIVATION; UPREGULATION; ZYMOGRAPHY; CULTURE MEDIUM; DRUG EFFECT; DRUG POTENTIATION; GROWTH, DEVELOPMENT AND AGING; IMMUNOHISTOCHEMISTRY; METABOLISM; MICROBIOLOGY; PHOSPHORYLATION; TUBERCULOUS MENINGITIS; TUMOR CELL LINE; WESTERN BLOTTING;

MYCOBACTERIUM TUBERCULOSIS;

BLOTTING, WESTERN; CELL LINE, TUMOR; CULTURE MEDIA, CONDITIONED; DEXAMETHASONE; DRUG SYNERGISM; ENZYME-LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; IMMUNOHISTOCHEMISTRY; INTERFERON TYPE II; INTERLEUKIN-1BETA; JANUS KINASES; MATRIX METALLOPROTEINASE 9; MONOCYTES; MYCOBACTERIUM TUBERCULOSIS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TISSUE INHIBITOR OF METALLOPROTEINASE-2; TUBERCULOSIS, CENTRAL NERVOUS SYSTEM; UP-REGULATION;

EID: 33846797918     PISSN: 08926638     EISSN: None     Source Type: Journal    
DOI: 10.1096/fj.06-6925com     Document Type: Article

References (64)

1. Thwaites, G. E., and Tran, T. H. (2005) Tuberculous meningitis: many questions, too few answers. Lancet Neurol. 4, 160-170
2. Dastur, D. K., Manghani, D. K., and Udani, P. M. (1995) Pathology and pathogenetic mechanisms in neurotuberculosis. Radiol. Clin. North Am. 33, 733-752
3. Fairbanks, L. D., Harris, J. C., Duley, J. A., and Simmonds, H. A. (2004) Nucleotide degradation products in cerebrospinal fluid (CSF) in inherited and acquired pathologies. Nucleosides Nucleotides 23, 1185-1187
4. Thwaites, G., Chau, T. T., Mai, N. T., Drobniewski, F., McAdam, K., and Farrar, J. (2000) Tuberculous meningitis. J. Neurol. Neurosurg. Psychiatry 68, 289-299
5. Elkington, P. T., Emerson, J. E., Lopez-Pascua, L. D., O'Kane, C. M., Horncastle, D. E., Boyle, J. J., and Friedland, J. S. (2005) Mycobacterium tuberculosis up-regulates matrix metalloproteinase-1 secretion from human airway epithelial cells via a p38 MAPK switch. J. Immunol. 175, 5333-5340
6. Elkington, P. T., and Friedland, J. S. (2005) Matrix metalloproteinases in destructive pulmonary pathology. Thorax 61, 259-266
7. Rivera, S., Jourquin, J., Ogier, C., Bernard, A., Charton, G., Tremblay, E., and Khrestchatisky, M. (2004) The MMP/TIMP system in the nervous system. Med. Sci. (Paris). 20, 55-60
8. Lo, E. H., Wang, X., and Cuzner, M. L. (2002) Extracellular proteolysis in brain injury and inflammation: role for plasminogen activators and matrix metalloproteinases. J. Neurosci. Res. 69, 1-9
9. Novak, U., and Kaye, A. H. (2000) Extracellular matrix and the brain: components and function. J. Clin. Neurosci. 7, 280-290
10. Asahi, M., Wang, X., Mori, T., Sumii, T., Jung, J. C., Moskowitz, M. A., Fini, M. E., and Lo, E. H. (2001) Effects of matrix metalloproteinase-9 gene knock-out on the proteolysis of blood-brain barrier and white matter components after cerebral ischemia. J. Neurosci. 21, 7724-7732
11. Matsuura, E., Umehara, F., Hashiguchi, T., Fujimoto, N., Okada, Y., and Osame, M. (2000) Marked increase of matrix metalloproteinase 9 in cerebrospinal fluid of patients with fungal or tuberculous meningoencephalitis. J. Neurol. Sci. 173, 45-52
12. Price, N. M., Farrar, J., Tran, T. T., Nguyen, T. H., Tran, T. H., and Friedland, J. S. (2001) Identification of a matrix-degrading phenotype in human tuberculosis in vitro and in vivo. J. Immunol. 166, 4223-4230
13. Svendsen, C. N. (2002) The amazing astrocyte. Nature 417, 29-32
14. Uhm, J. H., Dooley, N. P., Oh, L. Y., and Yong, V. W. (1998) Oligodendrocytes utilize a matrix metalloproteinase, MMP-9, to extend processes along an astrocyte extracellular matrix. Glia 22, 53-63
15. Yong, V. W. (1999) The potential use of MMP inhibitors to treat CNS diseases. Expert Opin. Investig. Drugs 8, 255-268
16. Gottschall, P. E., Yu, X., and Bing, B. (1995) Increased production of gelatinase B (matrix metalloproteinase-9) and interleukin-6 by activated rat microglia in culture. J. Neurosci. Res. 42, 335-342
17. Pereira, C. B., Palaci, M., Leite, O. H., Duarte, A. J., and Benard, G. (2004) Monocyte cytokine secretion in patients with pulmonary tuberculosis differs from that of healthy infected subjects and correlates with clinical manifestations. Microbes Infect. 6, 25-33
18. Kurisaki, H. (2000) Central nervous system tuberculosis with and without HIV infection-clinical, neuroimaging, and neuropathological study. Rinsho Shinkeigaku 40, 209-217
19. Wu, C. Y., Hsieh, H. L., Jou, M. J., and Yang, C. M. (2004) Involvement of p42/p44 MAPK, p38 MAPK, JNK and nuclear factor-kappa B in interleukin-1beta-induced matrix metalloproteinase-9 expression in rat brain astrocytes. J. Neurochem. 90, 1477-1488
20. Cagatay, T., Kiran, B., Yurt, S., Gulbaran, Z., Kosar, F., and Cagatay, P. (2005) Levels of tumour necrosis factor-alpha; and IL-1-beta; in newly diagnosed and multidrug resistant tuberculosis. Respirology 10, 290-294
21. Mastroianni, C. M., Paoletti, F., Lichtner, M., D'Agostino, C., Vullo, V., and Delia, S. (1997) Cerebrospinal fluid cytokines in patients with tuberculous meningitis. Clin. Immunol. Immunopathol. 84, 171-176
22. Donald, P. R., Schoeman, J. F., Beyers, N., Nel, E. D., Carlini, S. M., Olsen, K. D., and McCracken, G. H. (1995) Concentrations of interferon gamma, tumor necrosis factor alpha, and interleukin-1 beta in the cerebrospinal fluid of children treated for tuberculous meningitis. Clin. Infect. Dis. 21, 924-929
23. Mastroianni, C. M., Paoletti, F., Lichtner, M., D'Agostino, C., Vullo, V., and Delia, S. (1997) Cerebrospinal fluid cytokines in patients with tuberculous meningitis. Clin. Immunol. Immunopathol. 84, 171-176
24. Fassbender, K., Mielke, O., Bertsch, T., Muehlhauser, F., Hennerici, M., Kurimoto, M., and Rossol, S. (1999) Interferon-{gamma}-inducing factor (IL-18) and interferon-{gamma} in inflammatory CNS diseases. Neurology 53, 1104-1106
25. Levin, M., and Newport, M. (1999) Understanding the genetic basis of susceptibility to mycobacterial infection. Proc. Assoc. Am. Physicians 111, 308-312
26. Simmons, C. P., Thwaites, G. E., Quyen, N. T., Chau, T. T., Mai, P. P., Dung, N. T., Stepniewska, K., White, N. J., Hien, T. T., and Farrar, J. (2005) The clinical benefit of adjunctive dexamethasone in tuberculous meningitis is not associated with measurable attenuation of peripheral or local immune responses. J. Immunol. 175, 579-590
27. Aaronson, D. S., and Horvath, C. M. (2002) A road map for those who don't know JAK-STAT. Science 296, 1653-1655
28. Qing, Y., and Stark, G. R. (2004) Alternative activation of STAT1 and STAT3 in response to interferon-gamma. J. Biol. Chem. 279, 41679-41685
29. Caldenhoven, E., Buitenhuis, M., van Dijk, T. B., Raaijmakers, J. A., Lammers, J. W., Koenderman, L., and de Groot, R. P. (1999) Lineage-specific activation of STAT3 by interferongamma in human neutrophils. J. Leukoc. Biol. 65, 391-396
30. Roy, S. K., Hu, J., Meng, Q., Xia, Y., Shapiro, P. S., Reddy, S. P., Platanias, L. C., Lindner, D. J., Johnson, P. F., Pritchard, C., et al. (2002) MEKK1 plays a critical role in activating the transcription factor C/EBP-beta-dependent gene expression in response to IFN-gamma. Proc. Natl. Acad. Sci. U. S. A. 99, 7945-7950
31. Hu, J., Roy, S. K., Shapiro, P. S., Rodig, S. R., Reddy, S. P. M., Platanias, L. C., Schreiber, R. D., and Kalvakolanu, D. V. (2001) ERK1 and ERK2 activate CCAAAT/enhancer-binding protein-beta-dependent gene transcription in response to interferongamma. J. Biol. Chem. 276, 287-297
32. Ala-aho, R., Johansson, N., Grenman, R., Fusenig, N. E., Lopez-Otin, C., and Kahari, V. M. (2000) Inhibition of collagenase-3 (MMP-13) expression in transformed human keratinocytes by interferon-gamma is associated with activation of extracellular signal-regulated kinase-1,2 and STAT1. Oncogene 19, 248-257
33. Bartholome, E. J., Van Aelst, I., Koyen, E., Kiss, R., Willems, F., Goldman, M., and Opdenakker, G. (2001) Human monocyte-derived dendritic cells produce bioactive gelatinase B: inhibition by IFN-beta. J. Interferon. Cytokine Res. 21, 495-501
34. Dinney, C. P., Bielenberg, D. R., Perrotte, P., Reich, R., Eve, B. Y., Bucana, C. D., and Fidler, I. J. (1998) Inhibition of basic fibroblast growth factor expression, angiogenesis, and growth of human bladder carcinoma in mice by systemic interferon-alpha administration. Cancer Res. 58, 808-814
35. Ivanoff, A., Ivanoff, J., Hultenby, K., and Sundqvist, K. G. (1999) Infiltrative capacity of T leukemia cell lines: a distinct functional property coupled to expression of matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of metalloproteinases-1 (TIMP-1). Clin. Exp. Metastasis. 17, 695-711
36. Shin, K. Y., Moon, H. S., Park, H. Y., Lee, T. Y., Woo, Y. N., Kim, H. J., Lee, S. J., and Kong, G. (2000) Effects of tumor necrosis factor-alpha and interferon-gamma on expressions of matrix metalloproteinase-2 and -9 in human bladder cancer cells. Cancer Lett. 159, 127-134
37. Sanceau, J., Boyd, D. D., Seiki, M., and Bauvois, B. (2002) Interferons inhibit tumor necrosis factor-alpha-mediated matrix metalloproteinase-9 activation via interferon regulatory factor-1 binding competition with NF-kappa B. J. Biol. Chem. 277, 35766-35775
38. Ma, Z., Chang, M. J., Shah, R. C., and Benveniste, E. N. (2005) Interferon-{gamma}-activated STAT-1{alpha} suppresses MMP-9 gene transcription by sequestration of the coactivators CBP/p300. J. Leukoc. Biol. 78, 515-523
39. Elkington, P. T., Green, J. A., and Friedland, J. S. (2006) Filter sterilization of highly infectious samples to prevent false negative analysis of matrix metalloproteinase activity. J. Immunol. Methods. 309, 115-119
40. Leber, T. M., and Balkwill, F. R. (1997) Zymography: a singlestep staining method for quantitation of proteolytic activity on substrate gels. Anal. Biochem. 249, 24-28
41. Thwaites, G. E., Nguyen, D. B., Nguyen, H. D., Hoang, T. Q., Do, T. T., Nguyen, T. C., Nguyen, Q. H., Nguyen, T. T., Nguyen, N. H., Nguyen, T. N., et al. (2004) Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults. N. Engl. J. Med. 351, 1741-1751
42. Davies, S. P., Reddy, H., Caivano, M., and Cohen, P. (2000) Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem. J. 351, 95-105
43. Alessi, D. R., Cuenda, A., Cohen, P., Dudley, D. T., and Saltiel, A. R. (1995) PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo. J. Biol. Chem. 270, 27489-27494
44. Young, P. R., McLaughlin, M. M., Kumar, S., Kassis, S., Doyle, M. L., McNulty, D., Gallagher, T. F., Fisher, S., McDonnell, P. C., Carr, S. A., et al. (1997) Pyridinyl imidazole inhibitors of p38 mitogen-activated protein kinase bind in the ATP site. J. Biol. Chem. 272, 12116-12121
45. Ma, Z., Qin, H., and Benveniste, E. N. (2001) Transcriptional suppression of matrix metalloproteinase-9 gene expression by IFN-{gamma} and IFN-{beta}: critical role of STAT-1{alpha}. J. Immunol. 167, 5150-5159
46. Zhou, M., Zhang, Y., Ardans, J. A., and Wahl, L. M. (2003) Interferon-{gamma} differentially regulates monocyte matrix metalloproteinase-1 and -9 through tumor necrosis factor-{alpha} and caspase 8. J. Biol. Chem. 278, 45406-45413
47. Bianchini, F., D'Alessio, S., Fibbi, G., Del Rosso, M., and Calorini, L. (2006) Cytokine-dependent invasiveness in B16 murine melanoma cells: role of uPA system and MMP-9. Oncol. Rep. 15, 709-714
48. Ohga, S., Aoki, T., Okada, K., Akeda, H., Fujioka, K., Ohshima, A., Mori, T., Minamishima, I., and Ueda, K. (1994) Cerebrospinal fluid concentrations of interleukin-1 beta, tumour necrosis factor-alpha, and interferon gamma in bacterial meningitis. Arch. Dis. Child. 70, 123-125
49. Hickey, W. F. (2001) Basic principles of immunological surveillance of the normal central nervous system. Glia 36, 118-124
50. Graeber, M. B., and Streit, W. J. (1990) Microglia: immune network in the CNS. Brain Pathol. 1, 2-5
51. Rock, R. B., Hu, S., Gekker, G., Sheng, W. S., May, B., Kapur, V., and Peterson, P. K. (2005) Mycobacterium tuberculosis-induced cytokine and chemokine expression by human microglia and astrocytes: effects of dexamethasone. J. Infect. Dis. 192, 2054-2058
52. Catterall, J. B., Carrere, S., Koshy, P. J., Degnan, B. A., Shingleton, W. D., Brinckerhoff, C. E., Rutter, J., Cawston, T. E., and Rowan, A. D. (2001) Synergistic induction of matrix metalloproteinase 1 by interleukin-1alpha and oncostatin M in human chondrocytes involves signal transducer and activator of transcription and activator protein 1 transcription factors via a novel mechanism. Arthritis Rheum. 44, 2296-2310
53. Koshy, P. J., Lundy, C. J., Rowan, A. D., Porter, S., Edwards, D. R., Hogan, A., Clark, I. M., and Cawston, T. E. (2002) The modulation of matrix metalloproteinase and ADAM gene expression in human chondrocytes by interleukin-1 and oncostatin M: a time-course study using real-time quantitative reverse transcription-polymerase chain reaction. Arthritis Rheum. 46, 961-967
54. Ceyhan, M., Kanra, G., Ecevit, Z., Secmeer, G., Erdem, G., Akan, O., and Muftuoglu, O. (1997) Tumor necrosis factor-alpha and interleukin-1 beta levels in children with bacterial, tuberculous, and aseptic meningitis. Turk. J. Pediatr. 39, 177-184
55. Akalin, H., Akdis, A. C., Mistik, R., Helvaci, S., and Kilicturgay, K. (1994) Cerebrospinal fluid interleukin-1 beta/interleukin-1 receptor antagonist balance and tumor necrosis factor-alpha concentrations in tuberculous, viral, and acute bacterial meningitis. Scand. J. Infect. Dis. 26, 667-674
56. Asahina, M., Yoshiyama, Y., and Hattori, T. (2001) Expression of matrix metalloproteinase-9 and urinary-type plasminogen activator in Alzheimer's disease brain. Clin. Neuropathol. 20, 60-63
57. Helbecque, N., Hermant, X., Cottel, D., and Amouyel, P. (2003) The role of matrix metalloproteinase-9 in dementia. Neurosci. Lett. 350, 181-183
58. Seternes, O. M., Johansen, B., Hegge, B., Johannessen, M., Keyse, S. M., and Moens, U. (2002) Both binding and activation of p38 mitogen-activated protein kinase (MAPK) play essential roles in regulation of the nucleocytoplasmic distribution of MAPK-activated protein kinase 5 by cellular stress. Mol. Cell. Biol. 22, 6931-6945
59. New, L., Jiang, Y., and Han, J. (2003) Regulation of PRAK subcellular location by p38 MAP kinases. Mol. Biol. Cell. 14, 2603-2616
60. Dechow, T. N., Pedranzini, L., Leitch, A., Leslie, K., Gerald, W. L., Linkov, I., and Bromberg, J. F. (2004) Requirement of matrix metalloproteinase-9 for the transformation of human mammary epithelial cells by Stat3-C. Proc. Natl. Acad. Sci. U. S. A. 101, 10602-10607
61. Kaur, N., Kim, I. J., Higgins, D., and Halvorsen, S. W. (2003) Induction of an interferon-gamma Stat3 response in nerve cells by pre-treatment with gp130 cytokines. J. Neurochem. 87, 437-447
62. Ernst, M., and Jenkins, B. J. (2004) Acquiring signalling specificity from the cytokine receptor gp130. Trends Genet. 20, 23-32
63. Platanias, L. C. (2005) Mechanisms of type-1 and type-II interferon-mediated signalling. Nat. Rev. Immunol. 5, 375-386
64. Giannopoulou, M., Iszkula, S. C., Dai, C., Tan, X., Yang, J., Michalopoulos, G. K., and Liu, Y. (2006) Distinctive role of Stat3 and Erk-1/2 activation in mediating interferon-{gamma} inhibition of TGF-beta1 action. Am. J. Physiol. Renal Physiol. 290, F1234-1240